SCHEMBL10043890

SCHEMBL10043890

Cc1cc2c(cn1)cc(-c1cc(C(=O)Nc3ccc(C(C)O)cc3)ccc1C)c(=O)n2C

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.44
MAPK14 Q16539 9/20 0.42
POLB P06746 2/20 0.41
MAPT P10636 2/20 0.39
LMNA P02545 2/20 0.39
ALDH1A1 P00352 1/20 0.39
MAPK1 P28482 1/20 0.39
DDR2 Q16832 2/20 0.39
ABL1 P00519 4/20 0.38
MAPKAPK2 P49137 2/20 0.38
MAPK13 O15264 1/20 0.38
RAF1 P04049 1/20 0.38
PDGFRA P16234 1/20 0.38
MAPK12 P53778 1/20 0.38
KCNH2 Q12809 1/20 0.38
MAPK11 Q15759 1/20 0.38
LCK P06239 2/20 0.37
KIT P10721 2/20 0.37
KDR P35968 2/20 0.37
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10043922 0.88 MAPK14 (0.48) SYKMAPK14MAPTALDH1A1ABL1
SCHEMBL10043901 0.88 KCNQ3 (0.49) SYKMAPK14POLBMAPTABL1
SCHEMBL10043663 0.86 SYK (0.51) SYKMAPK14POLBMAPTLMNA
SCHEMBL10043705 0.85 MAPT (0.54) SYKMAPK14POLBMAPTALDH1A1
SCHEMBL10043889 0.85 SYK (0.43) SYKMAPK14POLBMAPTALDH1A1
SCHEMBL10043923 0.84 MAOB (0.53) SYKMAPK14POLBMAPTMAPKAPK2
SCHEMBL10043898 0.84 MAPK14 (0.47) SYKMAPK14ABL1MAPKAPK2MAPK13
SCHEMBL10043675 0.84 SYK (0.49) SYKMAPK14POLBMAPTABL1
SCHEMBL13438140 0.84 SMN1; SMN2 (0.46) SYKMAPK14POLBMAPTLMNA
SCHEMBL10043680 0.83 SYK (0.49) SYKMAPK14POLBMAPTABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-8106068-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2012-01-31 US disclosed
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2010-04-01 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-7678792-B2 Compositions and methods for modulating c-kit and PDGFR receptors IRM LLC (BM) 2010-03-16 US disclosed
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS IRM LLC (BM) 2008-07-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176846-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885MAPK14 117/4885POLB 4382/4885
US-20100081656-A1 COMPOSITIONS AND METHODS FOR MODULATING C-KIT AND PDGFR RECEPTORS FYN, FLT3, SRC SYK 42/4885MAPK14 117/4885POLB 4382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.